1620172-29-3Relevant academic research and scientific papers
TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS
-
Paragraph 0250; 0251, (2014/07/23)
Compounds according to Formula (I) and Formula (II) are potent inhibitors of PSMA. (I) or (II) Pharmaceutical compositions may include a complex of a radionuclide and a Formula (I) compound or a Formula (II) compound. Methods include using the radionuclide complex of a Formula (I) compound or a Formula (II) compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
